Detalhe da pesquisa
1.
S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability in multiple myeloma.
Haematologica
; 109(1): 256-271, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37470139
2.
Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis.
J Pathol
; 260(2): 112-123, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36807305
3.
Targeting the ß2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism.
J Pathol
; 259(1): 69-80, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36245401
4.
Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.
Cell Mol Life Sci
; 80(9): 249, 2023 Aug 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37578563
5.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433920
6.
Identifying patients with chronic lymphocytic leukemia without need of treatment: End of endless watch and wait?
Eur J Haematol
; 108(5): 369-378, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35030282
7.
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Br J Haematol
; 194(1): 120-131, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34036560
8.
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
BMC Cancer
; 21(1): 993, 2021 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34488662
9.
The anaphase-promoting complex/cyclosome: a new promising target in diffuse large B-cell lymphoma and mantle cell lymphoma.
Br J Cancer
; 120(12): 1137-1146, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31089208
10.
Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.
Haematologica
; 104(11): 2274-2282, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30923094
11.
Predicting cytogenetic risk in multiple myeloma using conventional whole-body MRI, spinal dynamic contrast-enhanced MRI, and spinal diffusion-weighted imaging.
Insights Imaging
; 15(1): 106, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38597979
12.
Comprehensive clinical and molecular analysis of 12 families with type 1 recessive cutis laxa.
Hum Mutat
; 34(1): 111-21, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22829427
13.
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
J Immunother Cancer
; 11(1)2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36650020
14.
A mini-review on aplastic anemia, illustrated by a case report on bone marrow hot pockets mimicking sclerotic bone metastases.
Acta Clin Belg
; 77(2): 410-415, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33433292
15.
Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach.
Front Cell Dev Biol
; 10: 879057, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35757005
16.
Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis.
J Exp Clin Cancer Res
; 41(1): 45, 2022 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35105345
17.
System Xc- inhibition blocks bone marrow-multiple myeloma exosomal crosstalk, thereby countering bortezomib resistance.
Cancer Lett
; 535: 215649, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35315341
18.
G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death.
Blood Adv
; 5(9): 2325-2338, 2021 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33938943
19.
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma.
Oncoimmunology
; 10(1): 2000699, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34777918
20.
Daratumumab With Cetrelimab, an Anti-PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 21(1): 46-54.e4, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33485428